Marie-Odile Roy

Marie-Odile Roy has extensive experience in the pharmaceutical and biotechnology industry. Marie-Odile currently holds the position of Head of R&D Portfolio Strategy & Operations at Pierre Fabre Group, where they oversee the development of non-clinical and clinical PK/Toxicology as well as biometry support for various therapeutic indications. Prior to this role, Marie-Odile served as the Head of PK/Toxicology/Biometry at Pierre Fabre, leading the unit responsible for non-clinical and clinical PK/Toxicology and providing statistical and data management support. Marie-Odile also worked as Head of Developability Assessment at Pierre Fabre.

Before joining Pierre Fabre, Marie-Odile held the position of Director of Pre-clinical Research & Development at the Biotherapies Institute of the Association Française contre les Myopathies (AFM). In this role, they supervised the preclinical development of novel chemical entities (NCE) and advanced therapy medicinal products (ATMP) targeting rare diseases, collaborating with clinical and regulatory departments to ensure efficient translation to clinical settings. Marie-Odile also played a key role in portfolio de-risking, project prioritization, and regulatory dossier preparations.

Marie-Odile's earlier experience includes working at Euroscreen as a Project Leader in GPCR Drug Discovery, where they also served as the Head of Compound Profiling in ADME-Tox & DMPK. At Euroscreen, they were involved in target discovery and validation for GPCR in CNS and inflammation. Prior to that, they worked at Astrazeneca R&D Montreal-Canada as a Research Scientist in Target Discovery, focusing on CNS and pain-related research. Marie-Odile also began their research career as a research scientist in cancer research at Aurelium Biopharma.

Marie-Odile Roy received their Doctor of Philosophy (Ph.D.) in Biochemistry, Biophysics, and Molecular Biology from the University of Montpellier from 1990 to 1997. Marie-Odile then pursued post-doctoral research at McGill University from 1997 to 2000 in the same field of study.